Altered antioxidant enzyme activity with severity and comorbidities of chronic obstructive pulmonary disease (COPD) in South Indian population by unknown
RESEARCH Open Access
Altered antioxidant enzyme activity with
severity and comorbidities of chronic
obstructive pulmonary disease (COPD) in
South Indian population
Asimuddin Mohammed1,2*, Vijayalakshmi Gutta1, Mohd Soheb Ansari4, Rajagopal Saladi Venkata3
and Kaiser Jamil2,4
Abstract
Background: Oxidative stress has been suggested in the pathogenesis of Chronic Obstructive Pulmonary Disease
(COPD) with an additional burden of diabetes, hypertension and cardiovascular disease. In the present study, we
investigated erythrocyte antioxidant enzymes activities in correlation to COPD severity and COPD comorbidities.
Methods: One hundred twenty seven subjects with COPD and 59 healthy controls participated in this study. COPD
severity was done based on the Global Initiative for Chronic Obstructive Lung Disease criteria. The erythrocytes enzyme
activities of superoxide dismutase (SOD), catalase (CAT), glutathione-s-transferase (GST), glutathione peroxidase (GPx),
glutathione reductase (GR) and total antioxidant status (TAS) were measured with spectrophotometric method.
Results: COPD patients showed significant decrease in TAS (p > 0.05), GST (p < 0.001) and GPx (p < 0.01) activities with
progression of the disease. In patients, FEV1 was negatively correlated with SOD, GR and positively correlated with GST
and GPx activities. Further, multivariate logistic regression analysis revealed GST (OR = 0.93; 95% CI = -0.10 – 0.01; p < 0.01)
, GPx (OR = 0.98; 95% CI = -0.03 – 0.00; p < 0.05) and TAS (OR = 0.95; 95% CI = -0.08 – 0.00; p < 0.05) were independently
associated with FEV1 in GOLD stage IV and GST (OR = 1.11; 95% CI = 0.04–0.18; p < 0.001) in GOLD stage II. Regression
analysis confirmed a significant difference in GPx activity in COPD – type 2 diabetes (OR = 0.04; 95% CI = -6.60 – 0.53;
P = 0.09), and GST activity in COPD – cardiovascular disease (OR = 2.51; 95% CI = 0.00 - 1.84; p < 0.05) patients when
compared to patients without comorbidities.
Conclusion: A significant decline in lung function may be associated with altered antioxidant enzyme activity due to
the strong correlation between GST and GPx with COPD severity. Our results also indicate that erythrocytes GST and GPX
activities are significantly associated with comorbidities, but only in COPD patients with type 2 diabetes and
cardiovascular disease.
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Background
Chronic obstructive pulmonary disease (COPD) is a dis-
ease characterized by irreversible and progressive airflow
obstruction that is associated with lung inflammation, ac-
cording to American Thoracic Society guidelines [1]. The
most common causes of COPD are cigarette smoking, en-
vironmental exposure to dust particles and air pollutants
such as allergens, bacterial and viral spores [2]. The lungs
are the organs that are continuously exposed to oxidants,
either generated from inside the body or from outside the
body due to exposure to air pollution or cigarette smoke.
These particles increase the levels of oxidants in the lungs,
and have the potential to interact with biological systems
to produce oxidative stress, which results in the destruc-
tion of alveoli, the tiny air sacs in the lungs where the ex-
change of oxygen and carbon dioxide takes place, and also
results in narrowing of airway lumen diameters. Oxidative
stress promotes inflammation of the airways of the lungs
as seen in COPD patients.
This causes an irreversible decrease in reduction of
forced expiratory volume in 1 s (FEV1) as seen in COPD
cases [3]. COPD is a major, ever increasing global health
problem due to increase in smoking rates and lifestyle
changes and is projected to be the fourth leading cause
of death worldwide by 2030 [4]. A report submitted by
National Commission on Macroeconomics and Health
(NCMH), showed that the incidence of COPD in India
may increase from 17.0 million (in the year 2006) to
22.2 million by 2016 [5].
Oxidative stress, being the major risk factor in the
pathogenesis of COPD, is caused by the generation of
free oxygen radicals (ROS) [6]. Excessive cigarette smok-
ing or environmental exposure to smoke and air-
pollutants has been shown to settle in the lungs, leading
to increased production of ROS causing oxidative stress
[7]. Another prominent source of ROS is either environ-
mental derived or cell-derived, both of these are directly
associated with many chronic respiratory lung diseases,
including COPD [8, 9]. These ROS categories include
superoxide anion (O2
.-), hydroxyl radical (.OH), hydrogen
peroxide (H2O2) and nitric oxide (NO.) radicals [10]. In
order to maintain the balance of oxidative stress caused
by ROS, the body has to balance between enzymatic and
non-enzymatic antioxidants [11, 12]. The main function
of antioxidant enzymes is to neutralize the free radicals
and transform them into safer (O2
-). Antioxidants en-
zymes, such as superoxide dismutase (SOD) which de-
toxifies the superoxide anion and converts into H2O2
and O2, a less toxic product. Catalase (CAT) enzyme
completes the detoxification process initiated by SOD
via decomposition of H2O2 to water and oxygen [13].
Glutathione peroxidase (GPx) is a family of selenium-
dependent and independent antioxidant enzymes [14].
There are six known isoforms of GPx and the most
abundant isoforms, GPx-1, is ubiquitously expressed in
the cytoplasm of all mammalian cells [15, 16]. The main
function of GPx is to detoxify hydrogen peroxide to H2O
and O2. However, it also detoxifies the lipid peroxides to
release water and alcohol [13]. Glutathione-s-transferase
(GST) is major cytosolic phase II detoxification enzymes
which inactivates reactive electrophiles by Glutathione
(GSH) dependent mechanism [7, 8]. Glutathione reductase
(GR) recycles the oxidized glutathione disulfide (GSSG)
using NADPH as the reducing co-factor and thereby main-
tains an appropriate intracellular GSH level in the cell [17].
There is evidence that erythrocyte GPx activity is
lower in smokers compared to non-smokers [18]. Few
studies report a direct relationship between forced ex-
piratory volume in 1 s (FEV1) and pathogenesis of
COPD [19, 20]. On the other hand, another study failed
to find significant relationship between FEV1 and plasma
antioxidant capacity [21]. It has been reported that
erythrocytes are more exposed to oxidative stress and
studies have shown that these cells are highly susceptible
to oxidative damage in the development and progression
of various diseases. In view of such conflicting reports,
we have taken up this study to investigate the role of anti-
oxidants in diseased patients. It is also known that comor-
bidities in COPD are known to cause difficulties in
diagnosis and cause economic burden to patients. Meta-
bolic complications, namely diabetes and metabolic syn-
drome are the most common comorbidities in COPD.
Besides, some reports have demonstrated that COPD pa-
tients have a relatively increased risk of developing lung
cancer, pulmonary hypertension and cardiovascular disease
[22]. There are evidences that cardiovascular disease and
COPD patients share the same risk factors i.e. smoking
and alcohol [23]. It is not surprising to note that pulmon-
ary hypertension which results in type 2 diabetes could also
lead to COPD with significant lower FEV1 values than in
non-diabetics [24]. However, it is not understood why
COPD patients are at greater risk of type 2 diabetes as
compared to non-diabetes subjects or vice-versa [25].
It has been a common practice to identify the antioxi-
dant enzyme levels in plasma or serum. Furthermore, in
the progression of COPD erythrocytes are highly suscep-
tible to oxidative damage. Therefore, the present study
aimed to investigate the erythrocyte antioxidant enzyme
activities in COPD patients and correlate these levels with
lung function test assessed as FEV1. It is also possible that
the comorbidities may further increase the risk of COPD
severity. We are not aware of any previous studies that ad-
dressed the erythrocyte antioxidant enzyme activities in
COPD patients with comorbid diseases such as type 2 dia-
betes, pulmonary hypertension and cardiovascular disease.
Hence, the present study also aims to investigate the rela-
tionship between the antioxidant enzymes activities of
COPD patients with comorbidities.
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Methods
Demographic details of patients
One hundred twenty seven COPD patients and 59
healthy controls were participated in this study. The data
regarding gender, age, body mass index (BMI) and smok-
ing status were analyzed. All study subjects underwent a
standardized clinical examination at the Outpatients
clinic at Mahavir Hospital and Research Centre, Hydera-
bad, India. The COPD patients and controls were in-
formed about the study and purpose; and gave written
informed consent before inclusion in the study group.
The study was conducted in accordance with the guide-
lines of Committee responsible for human studies as
guided by the “Declaration of Helsinki” and good clinical
practice. The Ethics Committee of Mahavir Hospital and
Research Centre – Hyderabad approved the study.
Inclusion criteria: All patients recruited had con-
firmed COPD as determined by the Pulmonologist. The
potential cases having symptoms such as chronic cough,
breathing problem and production of mucus or sputum
were reviewed by respiratory physiologist. Each patient
was checked 10–15 min after administration of 200 μg
of salbutamol. Only patients who showed airway ob-
struction reversibility <12% of forced expiratory volume
in 1 s (FEV1) and or forced vital capacity FVC, were
retained for the study. The predicted values for FEV1,
FVC and FEV1/FVC were generated for COPD severity.
The Pulmonary function test was performed using Mir
Spiro Lab II Spirometer (MIR s.r.l, Roma, Italy). At least
3 acceptable and two reproducible curves (the two high-
est FVC and FEV1 being within 200 ml of each other)
were obtained. Patients which showed highest values of
FEV1 were selected for analysis. Spirometry measure-
ments in COPD patients were performed as per Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [26]. The GOLD stage classification of disease
severity was done as per Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines [26].
GOLD stage I (mild): ≥ 80%; GOLD stage II (moderate):
50–70%; GOLD stage III (severe): 30–49% and GOLD
stage IV (very severe) < 30% predicted.
Among the selected COPD study group, we found
three types of comorbid diseases including type 2 dia-
betes, some cases with pulmonary hypertension and
some cases with cardiovascular disease. These were
noted for further analysis. Among the COPD patients
comorbid disease analyses were limited to subjects in
whom complete data on demographic factors, risk fac-
tors and baseline comorbid disease were available. The
59 volunteers selected as controls were recruited from
the general population (Among these three were ex-
smokers, 17 current smokers and 39 non-smokers) with







Age, years 51.02 ± 0.27 60.10 ± 0.31**
Male (n) 38 (64.40) 98 (77.16)
Female (n) 21 (35.59) 29 (22.83)
Weight (kg) 65.32 ± 1.50 61.69 ± 0.32**
Height (cms) 157.12 ± 1.04 158.50 ± 0.26
BMI (kg/m2) 26.43 ± 0.65 24.43 ± 0.20**
Smoking Status
Ex-smoker (n) 13 (22.03) 50 (39.37)
current smoker (n) 17 (28.81) 32 (25.19)
non-smoker (n) 29 (49.15) 45 (35.43
Spirometry parameter
FEV1, % of predicted 71.20 ± 1.26 36.21 ± 0.40***
FVC, % of predicted 83.99 ± 1.06 50.15 ± 0.34***
FEV1/FVC, % of predicted 97.56 ± 0.71 70.41 ± 0.46***
PaO2 (mmHg) 57.51 ± 0.11
SaO2 (%) 90.62 ± 0.19
COPD co-morbidities
Type 2 diabetes (n) 41 (32.28)
Pulmonary hypertension (n) 52 (40.94)
Cardiovascular disease (n) 27 (21.25)
Variables are expressed as Mean ± SEM or number (%), standard error of the
mean; Significance of difference to control: *p < 0.05, **p < 0.001, ***p < 0.001.
COPD Chronic Obstructive Pulmonary Disease, BMI Body Mass Index, FEV1 forced
expiratory volume in 1 s, FVC force vital capacity, FEV1/FVC forced expiratory
volume in 1 s/forced vital capacity ratio, PaO2 Partial pressure of oxygen,
SaO2 Arterial oxygen saturation, n number
Table 2 Association of significant clinical characteristics of the
COPD patients according to GOLD Stage classification using
Spirometry parameters
GOLD stage classification of COPD patients









FEV1, % predicted 60.08 ± 0.38** 38.85 ± 0.31** 20.76 ± 0.25**
FVC, % predicted 85.91 ± 0.47** 58.32 ± 0.38** 42.18 ± 0.37**
FEV1/FVC, % predicted 70.21 ± 0.46 67.18 ± 0.05** 50.55 ± 0. 04**
PaO2 (mmHg) 57.08 ± 0.27 57.60 ± 0.20 57.60 ± 0.16
SaO2 (%) 87.33 ± 0.33** 89.92 ± 0.34** 92.23 ± 0.29**
Variables are expressed as Mean ± SEM, standard error of the mean; All p values
were calculated using ANOVA with Bonferroni post hoc test. Non-significant p
values, p> 0.05, **p< 0.01. FEV1: GOLD stage II vs. III vs. IV, **p < 0.01; FVC: GOLD
stage II vs. III vs. IV **p < 0.01; FEV1/FVC: GOLD stage II vs III, p > 0.05; GOLD stage
II vs. III vs. IV, **p< 0.01; PaO2 (mmHg): GOLD stage II vs. III vs. IV, p > 0.05; SaO2
(%): GOLD stage II vs III vs. IV p > 0.05; GOLD stage II vs IV, **p< 0.01
COPD Chronic Obstructive Pulmonary Disease, GOLD Global initiative for chronic
Obstructive Lung Disease; GOLD stage classification: GOLD II- Moderate COPD,
GOLD III - Severe COPD, GOLD IV - Very severe COPD; FEV1 forced expiratory
volume in 1 s, FVC force vital capacity, FEV1/FVC forced expiratory volume
in 1 s/forced vital capacity ratio; PaO2 Partial pressure of oxygen, SaO2
Arterial oxygen saturation
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no respiratory problems. Inclusion criteria: Exclusion
criteria: All those subjects with very severe conditions,
pregnant women and children with severe cough were
excluded from the study.
Blood sample collection and processing
Blood samples from COPD patients and controls (5 ml/
individual) was collected in anticoagulant vacutainers
and processed immediately for analysis. Blood samples
were first centrifuged at 3000 rpm (5430R, Eppendorf,
Germany) for 10 min and the plasma was removed.
Then packed erythrocytes cells were washed three times
with 0.9% NaCl hypotonic solution and washed erythro-
cytes were lyses using ice-cold distilled water and stored
at -20 °C to determine the antioxidant enzyme estimation.
The erythrocyte hemolysate was prepared as mentioned
above using venous blood samples from the study group.
Estimation of antioxidant enzymes in erythrocytes
Erythrocyte hemolysates were used for the estimation of
SOD, CAT, GPx, GST, GR and TAS. SOD (EC 1.15.1.1)
activity was measured based on inhibition of pyrogallol
oxidation by the method of Marklund and Marklund
[27]. CAT (EC 1.11.1.16) activity was determined by the
method of Aebi [28]. Glutathione-s-transferase [GST]
(EC2.5.1.18) activity was assayed according to the
method described by Beutler [29] via measurement of
the conjugation product of GSH with 1-chloro-2, 4-
dinitrobenzene (CDNB). Glutathione peroxidase (EC
1.11.1.7) activity was measured according to the method
described by Flohe and Gunzler [30]. Glutathione reduc-
tase (EC 1.6.4.2) activity was measured by the method of
Carlberg and Mannervik [31]. The total antioxidant
power, expressed as the Ferric Reducing Ability of the
Plasma (FRAP) in erythrocytes, was analyzed by the
method described by Benzie and Strain [32]. The TAS
was determined using a different concentration of Ferric
(II) sulfate as standard. The results were expressed in
μM Fe2+/L equivalent.
Statistical analyses
All the demographic data and spirometric parameters
are presented as mean values ± Standard Error of the
Mean (SEM) using non-parametric statistics. Normality
distribution was analyzed using Shapiro-Wilk test and
the two-tailed t-test was used to analyze the statistical
significance for analyses between controls and COPD
patients. Comparisons between erythrocyte antioxidant
enzyme activities on disease severity GOLD stages I, II,
III and IV and COPD comorbidities were tested by
ANOVA; post hoc test for multiple comparisons using
Bonferroni correction were performed using GraphPad
Prism 6 (GraphPad Software Inc, San Diego, CA, USA).
GOLD stage I was excluded from the study. The
relationship between antioxidant enzyme activities and
FEV1 among COPD patients were evaluated using Pear-
son’s coefficients of correlation. Furthermore, a multi-
variate logistic regression model was constructed to
determine Odds ratios (OR), 95% confidence intervals
(95% CI) and significant of severity of COPD and COPD
comorbidities have been calculated in order to correlate
the erythrocyte antioxidant enzyme activities were analyze
using the XLSTAT statistical analysis (Addinsoft, New
York, NY, USA). A p-value of less than 0.05 (p < 0.05) was
considered as statistically significant.
Results
Normality analysis showed that all the variables were
normally distributed. The demographic characteristics of
COPD patients and healthy controls are presented in
Table 1. We found that the mean age of COPD patients
was > 60 years, whereas the mean age of control group
was >50 years old. The mean BMI was significantly
lower than that of controls (p < 0.05). The smoking status
in COPD patients in this study was as follows: there were
39.37% ex-smokers, 25.19% current smokers and 35.43%
non-smokers, whereas in controls we had 22.03% ex-
smokers, 28.18% current smokers and 49.15% non-
smokers respectively, Table 1. Spirometry measurements
in COPD patients as per GOLD stage classification of
Fig. 1 Schematic representation of percentage of patients in
COPD Comorbid
Table 3 Significant association of antioxidant enzyme activities
in cases and controls




Superoxide dismutase (U/mg protein) 87.56 ± 0.48 77.34 ± 0.48***
Catalase (U/mg protein) 98.34 ± 0.94 72.77 ± 0.60***
Glutathione s transferase
(U/mg protein)
42.05 ± 0.56 21.30 ± 0.33***
Glutathione peroxidase (U/mg protein) 63.77 ± 0.44 59.43 ± 0.50***
Glutathione reductase (U/mg protein) 77.08 ± 0.96 61.97 ± 0.60***
Total antioxidant status (μM Fe2+/l) 46.19 ± 0.27 41.64 ± 0.30***
Variables are expressed as mean ± SEM. Significance of difference between
COPD patients compared to controls: ***P < 0.001
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disease severity are presented in Table 2. There were no
patients belonging to GOLD stage I, GOLD stage II had
22.04%, GOLD stage III had 33.07 and 44.88% were in
GOLD stage IV. The pulmonary function test, assessed as
FEV1, FVC and the ratio of FEV1/FVC, showed signifi-
cantly decrease in the mean value from GOLD stage II to
IV in COPD patients (p < 0.001; ANOVA followed by
Bonferroni post hoc test) Table 2. No significant difference
in PaO2 between GOLD stages II to IV (p > 0.05) was ob-
served Table 2. A similar examination of SaO2 revealed a
significant increase in levels from GOLD stage II to IV
(p < 0.05). Comorbidities of COPD patients are sum-
marized in Fig. 1. Of the 127 patients diagnosed with
COPD, we found that 41 (52.07%) were Type II dia-
betic, 52 (74.93%) had pulmonary hypertension and
27 (34.29%) had cardiovascular disease.
A significant decrease in the first and second-step
antioxidant enzymes SOD and CAT activities was found
in COPD patients (p < 0.001). Similar significant de-
crease was also observed in the erythrocyte GST, GPx,
GR and TAS in COPD patients compared to controls
(p < 0.001), results are presented in Table 3. On
Fig. 2 Comparison of antioxidant enzyme activities according to severity of COPD using GOLD stage classification (GOLD stage II, III and IV): Erythrocytes
(a) SOD, superoxide dismutase; b CAT, catalase; c GST, glutathione-s-transferase; d GPx, glutathione peroxidase; e GR, glutathione reductase; expressed as
U/mg protein and (f) TAS, total antioxidant status; expressed as μM Fe2+/l. Data expressed as Mean ± SEM: standard error of the mean; Significant
of differences and respective p values **p < 0.001 are mentioned on the graph using One-way ANOVA followed by Bonferroni’s multiple
comparison post hoc test
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comparison of erythrocyte antioxidant enzyme activities
with severity of COPD, we found an increase in the mean
value of SOD and CAT in stages II to IV however, this in-
crease was not statistically significant (p > 0.05; Fig. 2a and
b). Conversely, a significant decrease in the mean value of
GST (p < 0.001) and GPx (p < 0.01) was observed in dis-
ease stages II, III and IV respectively, (Fig. 2c and d). In
contrast, the mean value of GR activity increased from
stage II to IV (p > 0.05; Fig. 2e). A decrease in the
mean value of TAS was observed in stages II, III and
IV (p > 0.05; Fig. 2f ).
Variations in Pearson’s coefficients of correlation values
between erythrocyte anti-oxidation enzyme activities with
FEV1 (% predicted) in COPD patients are presented in
Table 4. We observed negative correlation between
erythrocyte SOD, CAT and TAS with FEV1 in COPD pa-
tients (r = -0.182, r = -0.263 and r = -0.183; p < 0.05)
whereas GR was not statistically significant (r = -0.094;
p > 0.05). GST and GPx only entered as a model of anti-
oxidant enzymes, showed a significant positive correlation
with FEV1 in COPD patients (r = 0.630 and r = 0.030, re-
spectively) (Table 4). Further, correlation analysis was per-
formed with severity of COPD using GOLD stage
classification between erythrocyte antioxidant enzyme ac-
tivities with FEV1 is presented in Table 5. In COPD pa-
tients, FEV1 showed a significant negative correlation with
GST GOLD stage II (r = -0.735, p < 0.001) and a positive
correlation with GOLD stages III and IV (r = 0.098 and
r = 0.102, respectively). FEV1 correlated negatively with
GR activity in GOLD stages II and III (r = -0.474, p < 0.05
and r = -0.315, p < 0.05; respectively) and border line nega-
tive significant with GOLD stage III (r = -0.242, p < 0.07),
TAS also showed a significant negative correlation with
FEV1 (r = -0.383, p < 0.05) in GOLD stage III, Table 5. To
clarify whether the antioxidant enzyme activity and the se-
verity COPD were independently related, a multivariate
logistic regression analysis was performed (Table 6). Anti-
oxidant enzyme activities were log transformed prior to
analysis. Study variables with a Pearson correlation of
Table 4 Coefficients of correlation values between erythrocyte




Superoxide dismutase (U/mg protein) -0.182*
Catalase (U/mg protein) -0.263*
Glutathione s transferase (U/mg protein) 0.630**
Glutathione peroxidase (U/mg protein) 0.030
Glutathione reductase (U/mg protein) -0.094
Total antioxidant status (μM Fe2+/1) -0.183*
Significance of correlation between erythrocyte antioxidant enzyme activities
with FEV1 (% predicted). *p < 0.05, **p < 0.001, ‘r’ denotes Pearson correlation
coefficient
Table 5 Coefficients of correlation values between erythrocyte
anti-oxidation enzyme activities with FEV1 (% predicted) in COPD
patients according to GOLD stage classification


























Significance of correlation between erythrocyte antioxidant enzymes activities
with FEV1 (% predicted) according to GOLD stages:
¥
p < 0.07, Border line significance, *p < 0.05; **p < 0.001, ‘r’ denotes Pearson
correlation coefficient
Table 6 Multivariate logistic regression analysis adusted odds
ratio (95%CL) for erythrocyte anti-oxidation enzyme activities
with severity of COPD according to GOLD stage classification,
GOLD stage II, III and IV
Variables GOLD
stages
OR 95% CI p-values
Superoxide dismutase
(U/mg protein)
II 0.97 -0.05 – 0.01 0.173
III 0.99 -0.02 – 0.01 0.686
IV 1.00 -0.00 – 0.02 0.292
Catalase (U/mg protein) II 0.99 -0.02 – 0.00 0.321
III 0.99 -0.01 – 0.00 0.551
IV 1.00 -0.00 – 0.01 0.849
Glutathione s transferase
(U/mg protein)
II 1.11 0.04 – 0.18 <0.001
III 1.01 -0.01 – 0.05 0.284
IV 0.93 -0.10 – 0.01 <0.006
Glutathione peroxidase
(U/mg protein)
II 1.02 -0.00 – 0.05 0.082
III 1.00 -0.01 – 0.01 0.825
IV 0.98 -0.03 – 0.00 <0.034
Glutathione reductase
(U/mg protein)
II 0.98 -0.04 – 0.00 0.088
III 0.99 -0.01 – 0.00 0.507
IV 1.00 -0.00 – 0.01 0.313
Total antioxidant status
(μM Fe2+/1)
II 0.99 -0.08 – 0.07 0.886
III 0.97 -0.07 – 0.02 0.274
IV 0.95 -0.08 – 0.00 <0.049
Significance of difference between erythrocyte antioxidant enzymes activities
with FEV1 (% predicted) p < 0.05; OR odds ratio, CI confidence interval
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coefficient less than 0.11 that did not show multicollinear-
ity with COPD severity: GOLD stage II, III and IV. A
multivariate logistic regression analysis confirmed signifi-
cant independent association between GST (OR = 0.93;
95% CI = -0.10 – 0.01; p < 0.00), GPx (OR = 0.98; 95% CI
= -0.03 – 0.00; p < 0.05) and TAS (OR = 0.95; 95% CI
= -0.08 – 0.00; p < 0.05) and FEV1 in GOLD stage IV. A
significant association was observed with GST (OR = 1.11;
95% CI = 0.04 – 0.18; p < 0.001), whereas, a border line
significant of GPx (OR = 1.02; 95% CI = -0.00 – 0.05; p <
0.08) and GR (OR = 0.98; 95% CI = -0.04 – 0.00; p < 0.08)
activities was observed in GOLD stage II, Table 6.
The decrease in the mean value of SOD, CAT in pa-
tients of COPD with type 2 diabetes, pulmonary hyper-
tension and cardiovascular disease compared to healthy
controls are shown in (Fig. 3a and b). However, this de-
crease was not statistically significant (p > 0.05). Similar
result was also noticed in GST and GR activities in
COPD patients with type 2 diabetes, pulmonary hyper-
tension and cardiovascular disease when compared to
healthy controls (Fig. 3c and d). A significant decrease in
the GPx activity (p < 0.001; Fig. 3d) and TAS (p < 0.05;
Fig. 3f ) in COPD patients with type 2 diabetes were ob-
served compared to healthy controls. No significant dif-
ferences of GPx and TAS were observed in COPD
patients with pulmonary hypertension and cardiovascu-
lar disease. However, in COPD comorbidities multivari-
ate logistic regression analysis confirmed a border line
significant difference in GPx activity in COPD with T2D
(OR = 0.04; 95% CI = -6.60 - 0.53; p = 0.09), and GST ac-
tivity in COPD - CVD (OR = 2.51; 95% CI = 0.00 - 1.84;
p < 0.05) patients when compared to non-comorbid pa-
tients, Table 7.
Discussion
It is now evident that COPD is a leading cause of hospital-
izations in adults, particularly older people. In fact, recent
medical research indicates that antioxidants eventually
could represent a promising therapy for COPD. Further,
comorbidities have been a common cause, contributing to
many of these ICU hospitalizations. This investigation has
determined important risk factors in COPD namely the
role of erythrocyte antioxidants related to disease severity.
An important feature in the pathogenesis of COPD is oxi-
dative stress. The relationship between COPD and oxida-
tive stress parameters has been extensively studied in
different populations across the world [33, 34], but very
few studies are available in the Indian population, espe-
cially in south India [35]. This study showed that COPD
patients had decreased SOD activity as compared to con-
trols, which has been one of the most consistent findings
across several studies in many countries [36]. In the
present study, CAT activity was found to be reduced in
COPD patients. Consistent with our result, a study in
erythrocyte red blood cells showed decreased CAT activity
in patients with COPD [35, 36]. In contrast, a study on
single nucleotide polymorphism in CAT gene (-262 C > T)
showed that erythrocyte catalase activity was higher in
COPD patients with the C/C genotype, and with the com-
bined C/T and T/T genotypes, than in healthy controls
[37]. Our study supports the finding of Tavilani et al.,
which reported an increase in SOD and CAT activities in
alveolar macrophages of elderly smokers [38]. Kirkil et al.
reported that the plasma levels of SOD and CAT de-
creased in the COPD group [39]. However, we found a
dramatic increase in SOD and CAT activities among pa-
tients with more severe COPD. It was found that erythro-
cyte SOD and CAT activities gradually increased from
GOLD stages I to IV in COPD patients, which is sup-
ported by previous reports [36–41]. Indeed, various stud-
ies [40–42] except one study [7] have suggested that
certain markers of oxidative stress may be related to to-
bacco smoking or to the severity of COPD.
In the present study, we found that erythrocyte GST
activity significantly decreased in COPD patients. A pos-
sible explanation for this decrease in activity of GST
could be that in COPD patients the increase in toxic
substrates in the body, reduces the GST activity which
was inversely proportional to the increased FEV1. Also it
is known that GST is influenced by nuclear factor,
erythroid-derived 2, like 2 (Nrf2), a transcription factor
that contributes to the induction of several protective
enzymes during oxidative stress [43]. Another possible
explanation could be due to the high levels of GSH in
the epithelial lining of the lungs, which regulate GSH
homeostasis by the GST enzymes that participate in the
transport and detoxification mechanism.
Hence it is suggested that there may be a strong asso-
ciation of GST with lung function at the molecular level
[44–48]. Interestingly, in this investigation, we also
found GST activity was not only lower in COPD but also
progressively decreased with the severity of COPD dis-
ease. Our study observed not only lowered level of GPx
activity in COPD patients, but also a uniform decrease
in GPx activities from GOLD stage II to IV. These find-
ings suggest that the lower activity of GPx in erythro-
cytes may be associated with the severity of COPD.
However, there is recent evidence suggesting that trans-
genic GPx-1 mice protect lungs from cigarette smoke-
induced lung inflammation [49]. Our present study
found a significant positive correlation between GPx and
FEV1 in COPD patients.
It was observed that erythrocyte GR activity was lower
in COPD patients, similar findings were also reported by
a few authors [38, 50] whereas, Gosker et al. reported an
increase glutathione activity in skeletal muscle of pa-
tients with COPD [51]. This investigation supports the
fact that in COPD patients oxidative stress deactivates
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the regulatory enzymes such as GPx, GST and GR in-
volved in the GSH/GSSG redox system which may be
involved in the protection of cellular and mitochondrial
functions in the lungs. Activity of GR increased from
GOLD stage II to IV, TAS in erythrocytes was lower in
COPD patients. A decrease in TAS suggests that there
was an increase in oxidative stress in COPD patients;
Rahman et al [52] also reported similar findings. With
the increase in severity of COPD from GOLD stage II to
IV we observed a significant decrease in the level of
TAS. Correlation analysis revealed a significant negative
correlation between erythrocyte SOD, CAT, GR and
TAS with FEV1 in COPD patients. Previously a signifi-
cant positive correlation between SOD and CAT with
FEV1 was described in erythrocytes of COPD patients
[35, 36]. One reason for failing to find a significant posi-
tive correlation between erythrocyte SOD or CAT and
FEV1 may be due to the phenomenon that various en-
zymatic systems differ substantially in their responses to
smoking-induced increases in oxidative stress [53].
In this study, of all the enzymes assayed, only GST and
GPx showed a significant positive correlation with FEV1
Fig. 3 Antioxidant enzyme activities in COPD patients with T2D, PHT and CVD and compared with the healthy controls. Erythrocytes (a) SOD,
superoxide dismutase; b CAT, catalase; c GST, glutathione-s-transferase; d GPx, glutathione peroxidase; e GR, glutathione reductase; expressed as U/mg
protein and (f) TAS, total antioxidant status; expressed as μM Fe2+/l. Data expressed as Mean ± SEM: standard error of the mean; Significance of difference
between COPD and type 2 diabetes (T2D), pulmonary hypertension (PHT) and cardiovascular disease (CVD) to control: Significant differences and
respective p values *p < 0.05, **p< 0.001 are mentioned on the graph using one-way ANOVA followed by Bonferroni’s multiple comparison post hoc test
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in COPD patients. Previous reports have also found a
significant positive correlation between erythrocytes
GST activity [35] and GPx [36] with lung function,
reflected by FEV1. In agreement with the positive correl-
ation of GST and GPx in erythrocyte of COPD patients,
a recent study has shown a significant direct relationship
between FEV1 and erythrocyte GPx activity [48]. To our
knowledge, there are no previous studies which have
evaluated the erythrocytes antioxidant enzyme activities
correlating with disease severity using pulmonary func-
tion test assessed as FEV1 in COPD. We found that
SOD and GPx activities were positively correlated with
FEV1. Conversely, CAT, GST, GR and TAS showed sig-
nificant negative correlation with FEV1. The risk con-
ferred by GST and GPx towards progression of the
COPD severity was further evaluated using multinomial
logistic regression analysis by taking GOLD stages as ref-
erence category. Increase in GST and GPx activities was
found to confer greater risk of progression to GOLD
stage II and IV. Kluchová et al [48] reported a similar
trend. In their study, the authors measured and com-
pared GPx activity in patients with moderate and severe
COPD. They found that a significant direct relationship
between FEV1 and erythrocyte GPx activity with severity
of COPD. Our findings extend those of Duthie et al.
who reported that erythrocyte GPx activity is associated
not only with smoking status but also with severity of
COPD [54]. The significant correlation found between
the enzymes and FEV1 suggests that decrease in antioxi-
dant enzyme activities might be the result of greater air-
way obstruction in COPD patients.
An interesting finding in the current analysis was the
antioxidant enzyme activities in COPD comorbidities.
We found no significant variations in erythrocyte SOD,
CAT, GST and GR activity in COPD patients with type 2
diabetes, pulmonary hypertension and cardiovascular
disease compared to control group. Whereas, erythro-
cyte GPx activity and TAS showed a significant decrease
in the mean value of COPD patients with type 2 dia-
betes. Joppa et al. also reported a significant decrease in
the GPx activity in erythrocyte of COPD patients with
and without pulmonary hypertension [55]. Some of the
previous finding of Orhan et al. showed a significant
increase in plasma GPx activity in hypertensive pre-
eclamptic pregnancy and also in insulin dependent dia-
betic pregnancy [56]. Further, it was observed that the
standard dietary treatment for type 2 diabetic patients
produced an increase of the SOD and GPx activities [57].
However, this may suggest that the COPD comorbidi-
ties are an independent risk factor for the development
of COPD. This finding was substantiated by multivariate
logistic regression analysis, which demonstrated that the
GPx activity was significantly independently association
of COPD – type 2 diabetes. Whereas, our present study
showed that there was no statistically significant inde-
pendent association of antioxidant enzyme activity in
COPD – pulmonary hypertension. Similar finding was
report by Al Shebly et al [58]; this study found no statis-
tically significant difference in plasma GSH-Red activity
during labor in diabetic, hypertensive, and control
women. More recently, it was clarified that a significant
increase of GPx and GSH activities in hypertensive dis-
orders of pregnant women.
Logistic regression analysis of comorbidities, in our
study, showed significant difference in GST activity be-
tween COPD - cardiovascular disease patients and GPx
activity in COPD - type 2 diabetes patients and patients
without comorbidities, suggesting that these enzymes
could serve as a critical marker to assess oxidative dam-
age in COPD patients with cardiovascular disease and
type 2 diabetes. Conversely, there was no significant dif-
ference in the activities of the other antioxidant enzymes
in patients with and without comorbidities, which could
indicate that these comorbidities may not confer signifi-
cant additive oxidative stress in the COPD patients.
Therefore, we propose that elevated level of GPx activity
in COPD patients with type 2 diabetes may be a useful
Table 7 Multivariate logistic regression analysis adusted odds
ratio (95%CL) for antioxidant enzyme activities with COPD




OR 95% CI p-values
Superoxide dismutase
(U/mg protein)
T2D 1.99 -1.11 – 2.49 0.453
PHT 1.61 -0.57 – 1.53 0.374
CVD 2.32 -0.35 – 2.04 0.169
Catalase (U/mg protein) T2D 1.98 -0.62 – 2.00 0.306
PHT 0.80 -1.14 – 0.70 0.642
CVD 1.77 -0.30 – 1.45 0.199
Glutathione s transferase
(U/mg protein)
T2D 0.90 -1.39 – 1.18 0.873
PHT 1.41 -0.57 – 1.26 0.462
CVD 2.51 0.00 – 1.84 <0.049
Glutathione peroxidase
(U/mg protein)
T2D 0.04 -6.60 – 0.53 <0.096
PHT 0.82 -1.12 – 0.72 0.677
CVD 0.63 -1.52 – 0.59 0.392
Glutathione reductase
(U/mg protein)
T2D 0.58 -1.76 – 0.70 0.400
PHT 0.52 -1.67 – 0.40 0.228
CVD 0.57 -1.60 – 0.49 0.299
Total antioxidant status
(μM Fe2+/l)
T2D 1.04 -1.07 – 1.16 0.934
PHT 1.26 -0.61 – 1.08 0.589
CVD 1.69 -0.45 – 1.50 0.291
Significance of difference between erythrocyte antioxidant enzyme activities
with COPD comorbidities: type 2 diabetes (T2D), pulmonary hypertension (PHT)
and cardiovascular disease (CVD) p < 0.05; Border line significance: if p < 0.09; OR
odds ratio, CI confidence interval
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biomarker linked to an increase in oxidative stress. Sur-
prisingly, our present study showed no significant en-
zyme activities in COPD patients with pulmonary
hypertension. However, there are a number of conflict-
ing reports as well [59, 60]. Hence, our study may have
useful clinical implications in view of increased under-
standing of COPD risk parameters with comorbid
diseases.
Conclusions
The present study provides a strong evidence for the
oxidant-antioxidant imbalance in the pathogenesis of
COPD. Our study is the first, to our knowledge, to
examine the correlation between FEV1 and antioxidant
enzyme activities among the different stages of COPD
and highlights a strong correlation between FEV1, GST
and GPx enzyme activity with severity of the COPD dis-
ease. This study also demonstrated for the first time that
there exits an oxidative stress in COPD patients with co-
morbidities such as type 2 diabetes, pulmonary hyper-
tension and cardiovascular disease. Further, it is likely
that antioxidants may have in future combination ther-
apies for COPD patients. This study may have useful
clinical implications in view of increased understanding
of COPD risk parameters. It has also been recognized
that additional burden of comorbidities has negative im-
pact on economies and also patient related outcomes.
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